News stories about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.4649590776594 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Drug industry on tenterhooks as Maryland price-gouging law nears – Reuters (reuters.com)
- CVC Nears Deal for Teva’s European Women’s Health Assets – Bloomberg (bloomberg.com)
- Teva’s New CEO Is A Blessing (seekingalpha.com)
- The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (finance.yahoo.com)
- Is It Too Late To Buy Teva Pharmaceutical Industries Limited (TEVA)? (finance.yahoo.com)
Several equities analysts have recently commented on TEVA shares. Royal Bank Of Canada set a $38.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Friday, June 16th. Mizuho raised shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $25.00 to $30.00 in a research report on Thursday, June 15th. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 target price for the company. in a research report on Monday, May 22nd. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 31st. Finally, BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Five equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $31.42.
Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 1.42% during trading on Friday, reaching $18.10. 20,965,252 shares of the company traded hands. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $52.01. The firm’s market capitalization is $18.39 billion. The company has a 50 day moving average price of $19.41 and a 200 day moving average price of $28.68.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.25 EPS. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were given a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 1.88%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.
TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Earns Daily News Sentiment Score of 0.12” was first reported by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-receiving-somewhat-positive-news-coverage-accern-reports/1565430.html.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.